Sanctuary Advisors LLC Acquires 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Sanctuary Advisors LLC grew its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 36.0% in the fourth quarter, Holdings Channel reports. The firm owned 24,433 shares of the company’s stock after buying an additional 6,474 shares during the quarter. Sanctuary Advisors LLC’s holdings in 10x Genomics were worth $368,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics in the third quarter worth $35,000. Blue Trust Inc. grew its holdings in shares of 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC grew its holdings in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the fourth quarter worth $52,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of 10x Genomics by 1,108.9% in the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after acquiring an additional 2,240 shares during the period. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Down 7.9 %

Shares of 10x Genomics stock opened at $9.85 on Tuesday. The stock’s 50-day simple moving average is $13.90 and its 200-day simple moving average is $16.67. 10x Genomics, Inc. has a 52 week low of $9.77 and a 52 week high of $45.60. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -6.48 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Stifel Nicolaus cut their price objective on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Wednesday, February 19th. Canaccord Genuity Group cut their price target on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. cut their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.57.

Insider Activity

In other news, Director Alan Mateo bought 40,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the sale, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.